Moleculin Biotech
MBRX
18 hedge funds and large institutions have $5.61M invested in Moleculin Biotech in 2021 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
246% more capital inflows, than outflows
Capital inflows: $532K | Capital outflows: $154K
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
38% more funds holding
Funds holding: 13 → 18 (+5)
0.56% more ownership
Funds ownership: 10% → 10.57% (+0.56%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$106K |
| 2 |
Virtu Financial
New York
|
+$106K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$88.7K |
| 4 |
Renaissance Technologies
New York
|
+$71K |
| 5 |
Two Sigma Securities
New York
|
+$53.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Truist Financial
Charlotte,
North Carolina
|
-$88K |
| 2 |
Raymond James & Associates
St Petersburg,
Florida
|
-$43K |
| 3 |
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$17.7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$4K |
| 5 |
Global Retirement Partners
San Rafael,
California
|
-$1K |
MBRX Hedge Fund Activity: Q4 2021 in Review
18 of the 6,522 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q4 2021, worth a combined $5.61M — down 35% from $8.57M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new MBRX positions and 2 closed out — a net gain of 5 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Sigma Planning Corp, opening a new position worth an estimated $106K. The largest seller was Truist Financial, exiting entirely with an estimated $88K sold.
- 18 institutional investors held Moleculin Biotech (MBRX) as of Q4 2021, up from 13 in Q3 2021.
- Funds reported $5.61M of Moleculin Biotech stock for Q4 2021, down 35% quarter-over-quarter.
- 7 funds opened new Moleculin Biotech positions in Q4 2021 and 2 closed out, a net change of +5 holders.
- The largest Moleculin Biotech buyer in Q4 2021 was Sigma Planning Corp, an estimated $106K added.
- The largest Moleculin Biotech seller in Q4 2021 was Truist Financial, an estimated $88K sold.
Based on aggregated 13F filings for Q4 2021.